AllCells understands the complexities of biomedical research. Following stringent protocols is paramount, and staying up to date on scientific discoveries is a principle endeavor. To ensure the quality, viability, and purity of AllCells’ products, the links below are dedicated to providing AllCells’ clients with technical protocols and educational resources to optimize their experiments.

Storage & Thawing Protocol

To ensure the quality, viability, and purity of our products, AllCells adheres to a consistent method for cell storage and thawing. By strictly following an in-depth, step-by-step protocol, AllCells’ clients can depend on reliable results. Continue reading for additional precautions and safety advisories.


Counting Protocol

To determine the number of viable cells in a given sample, researchers need to utilize a proven protocol for precisely counting their cells. AllCells has developed a protocol that is based on scientifically-proven techniques and methods for counting cells.


Shipping Network Map

Shipping & Delivery Options

Product integrity, delivery speed, and optimized pickup times – AllCells’ shipping principles. To deliver on these principles, AllCells utilizes an industry-leading AeroSafe Global Shipping Package, customer-focused delivery options, and an optimized processing schedule. You can trust AllCells to deliver the highest quality cells on time and on your schedule.




Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII

Alexander Sternjak, Fei Lee, Oliver Thomas, Mercedesz Balazs, Joachim Wahl

AMG 596 is a bispecific T-cell engager (BiTE) immuno-oncology therapy in clinical development for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with limited therapeutic options. AMG 596 is composed of two single-chain variable fragments that simultaneously bind to the tumor-specific antigen, EGFR variant III (EGFRvIII), on GBM cells and to CD3 on T cells...



Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Claire L. Langrish, J. Michael Bradshaw, Michelle R. Francesco, Timothy D. Owens

Bruton tyrosine kinase (BTK) is expressed in B cells and innate immune cells, acting as an essential signaling element in multiple immune cell pathways. Selective BTK inhibition has the potential to target multiple immune-mediated disease pathways. Rilzabrutinib is an oral, reversible, covalent BTK inhibitor designed for immune-mediated diseases. We examined the pharmacodynamic profile of rilzabrutinib and its preclinical...


Customer Service

How Can We Help You?

Looking for research tips? Need help sourcing materials? How about a few more articles on therapies or processes? At AllCells, we believe that partnerships create the best pathways to success. Our Customer Success Team has years of industry experience and a wealth of resources to help you get the most out of your cellular products. We’re only a few clicks away.

Contact Us